WestEnd Advisors’s Idexx Laboratories IDXX Stock Holding History

WestEnd Advisors’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.58K	Buy	3 +1	+50%	+$561	﹤0.01%	215
2026 Q1	$1.12K	Hold	2	–	–	﹤0.01%	224
2025 Q4	$1.35K	Sell	2 -1	-33%	-$681	﹤0.01%	204
2025 Q3	$1.92K	Hold	3	–	–	﹤0.01%	158
2025 Q2	$1.61K	Hold	3	–	–	﹤0.01%	168
2025 Q1	$1.26K	Buy	3 +2	+200%	+$868	﹤0.01%	189
2024 Q4	$413	Hold	1	–	–	﹤0.01%	195
2024 Q3	$505	Hold	1	–	–	﹤0.01%	171
2024 Q2	$487	Hold	1	–	–	﹤0.01%	162
2024 Q1	$540	Hold	1	–	–	﹤0.01%	147
2023 Q4	$555	Hold	1	–	–	﹤0.01%	151
2023 Q3	$437	Buy	+1	New	+$499	﹤0.01%	167
2023 Q1	–	Sell	-1	Closed	-$479	–	152
2022 Q4	$408	Hold	1	–	–	﹤0.01%	163
2022 Q3	$0	Hold	1	–	–	﹤0.01%	233
2022 Q2	$350	Buy	+1	New	+$408	﹤0.01%	155
2022 Q1	–	Sell	-1	Closed	-$526	–	144
2021 Q4	$658	Buy	+1	New	+$628	﹤0.01%	136
2021 Q3	–	Hold	0	–	–	–	126
2021 Q2	–	Hold	0	–	–	–	125

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

WestEnd Advisors's IDXX Position: Q2 2026 in Review

WestEnd Advisors increased its Idexx Laboratories (IDXX) stake by 50% in Q2 2026, buying an estimated $561 and bringing the position to 3 shares worth $1.58K. The position accounts for ﹤0.01% of the portfolio, ranked #215.

WestEnd Advisors first reported a position in IDXX in Q4 2021 and has held it in 16 quarters since. The position peaked at $1.92K in Q3 2025. 1,301 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

WestEnd Advisors held 3 shares of Idexx Laboratories worth $1.58K as of Q2 2026.
WestEnd Advisors bought 1 Idexx Laboratories share in Q2 2026, an estimated $561.
Idexx Laboratories made up ﹤0.01% of WestEnd Advisors's portfolio in Q2 2026, its #215 holding.
WestEnd Advisors first reported a position in Idexx Laboratories in Q4 2021 and has held it in 16 quarters since.
WestEnd Advisors's Idexx Laboratories position peaked at $1.92K in Q3 2025.
1,301 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on WestEnd Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.